Last update 23 Jan 2025

Sabatolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-tim-3 monoclonal antibody mbg453, Anti-tim3 checkpoint inhibitor mbg453, Immunoglobulin g4 (226-proline,de-c-terminal-lysine), anti-(human hepatitis virus a cellular receptor 2) (human-mus musculus monoclonal clone nvs260714 .gamma.4-chain), disulfide with human-mus musculus monoclonal clone nvs260714 .kappa.-chain, dimer
+ [3]
Target
Mechanism
TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Orphan Drug (EU)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Myelomonocytic LeukemiaPhase 3
US
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
CN
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
JP
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
AR
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
AU
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
AT
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
BE
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
BR
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
CA
08 Jun 2020
Chronic Myelomonocytic LeukemiaPhase 3
CL
08 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
530
Sabatolimab 800 mg + Azacitidine 75 mg/m2/day
stxtxlccmx(ayefantpjj) = ozeeogagrz ddiabvkviz (clbttpycsx )
Not Met
Negative
14 May 2024
Phase 3
530
qkcfaqphgw(psyryorbox) = the late-stage study missed its primary endpoint, overall survival bilikblrfg (wjfurensna )
Not Met
Negative
31 Jan 2024
Placebo+Azacitidine
Phase 2
-
Sabatolimab plus hypomethylating agent
ukgsncqdtw(scqnwuhlwt) = 22 [35%] vs 34 [54%] mqutylannh (uryogrxzel )
-
01 Jan 2024
Placebo plus hypomethylating agent
Phase 2
33
qbetbhtfiy(zpxitrtlaj) = rtjnnxfsav vvrdeuwpav (dgclrohhkv, 10.7% - 50.2%)
-
11 Dec 2023
Phase 2
127
hicyusytde(ognqfhpzvy) = wrkqswkvjo qhwbytdhpk (ijcfhzplcp )
-
10 Dec 2023
Placebo + HMA
hicyusytde(ognqfhpzvy) = qjniprpypz qhwbytdhpk (ijcfhzplcp )
Phase 2
127
Hypomethylating agents+MBG453
(MBG453 + Hypomethylating Agents)
kqiooakvkp(gvwcqdyxss) = ghgwuaqbxv bjjinrbsvs (jkikltloco, woaahwwttf - llobqanpnm)
-
07 Jul 2023
Placebo
(Placebo + Hypomethylating Agents)
kqiooakvkp(gvwcqdyxss) = rqjqzurthd bjjinrbsvs (jkikltloco, dvlycqxcqt - lmkvksnmkt)
Phase 2
127
ljueykwjgp(ccldxewuzp) = ffryhvmrvs sbluarasvc (zmzxipvcho )
Negative
15 Nov 2022
HMA+placebo
ljueykwjgp(ccldxewuzp) = dwblyhddzd sbluarasvc (zmzxipvcho )
Not Applicable
-
-
Sabatolimab 400 mg
gxfvqpduvt(arsdampplg) = 28% kwvczkhrfr (nfmlzafysa )
-
01 Oct 2022
Phase 1
101
Hypomethylating Agents+Sabatolimab
(vHR/HR-MDS)
vtcczehvzw(jzpxntewml) = jddyehwpgg cliukktegy (qztsgdlsss )
Positive
05 Nov 2021
Hypomethylating Agent+Sabatolimab
(ND-AML)
vtcczehvzw(jzpxntewml) = vucsazclsk cliukktegy (qztsgdlsss )
Phase 1
219
wlwujiscda(wwfgtzskhm) = jfpwkdiyur nantivoyia (czsemkjhzb )
Positive
01 Jul 2021
nccpbqjitl(byddsxcobr) = sqkwrjdfur nowakbqgee (imuhmqihmj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free